GSK and Google form bioelectric meds company

1 August 2016

UK pharma major GlaxoSmithKline (LSE: GSK) has announced an agreement with Verily Life Sciences – formerly Google Life Sciences – to form Galvani Bioelectronics, a new company aimed at researching, developing and commercializing bioelectric medicines.

GSK will hold a 55% equity interest in the new jointly-owned company and 45% will be owned by Verily, which is a subsidiary of Alphabet, a US conglomerate which is the parent company of technology giant Google (Nasdaq: GOOGL).

Galvani Bioelectronics will be headquartered in the UK, with the parent companies contributing existing intellectual property rights and an investment of up to £540 million ($713.6 million) over seven years, subject to successful completion of various discovery and development milestones.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK